Cybin (NASDAQ:HELP) Stock Price Up 6.1% on Analyst Upgrade
Market Beat·- Cybin Inc. shares rose 6.1% after TD Cowen raised its price target from $8.00 to $62.00 with a buy rating. - Several institutional investors recently modified their holdings in the company, which holds a consensus buy rating and an average price target of $48.60. - The clinical-stage biopharmaceutical company reported an EPS of ($0.91) for its latest quarter, missing consensus estimates.Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
Market Beat·- Bank of America Corp DE raised its stake in Relay Therapeutics, Inc. by 86.1% during the first quarter, owning 1,937,695 shares valued at $19,280,000. - Institutional investors and hedge funds collectively own 96.98% of the company's stock, alongside notable insider stock sales and recent quarterly earnings reports. - Analysts currently maintain a consensus Moderate Buy rating for the stock with an average target price of $25.83.Bank of America Corp DE Decreases Position in Par Pacific Holdings, Inc. $PARR
Market Beat·- Bank of America Corp DE decreased its holdings in Par Pacific Holdings, Inc. by 45.6% in the first quarter, retaining 293,552 shares valued at $18,388,000. - Par Pacific reported strong quarterly results with an EPS of $10.10 and revenue reaching $2.97 billion, representing a 56.8% increase year-over-year. - The company currently maintains a market capitalization of $3.86 billion alongside a consensus analyst rating of moderate buy.Howard Hughes Holdings Inc. $HHH Position Boosted by Bank of America Corp DE
Market Beat·- Bank of America Corp DE raised its stake in Howard Hughes Holdings Inc. by 14.8 % during the first quarter to own 304,520 shares valued at $19,264,000. - Several other institutional investors and hedge funds also modified their holdings, bringing total institutional ownership to 93.83 %. - The real estate development company recently reported strong quarterly earnings of $2.68 EPS and $1.12 billion in revenue, reflecting a 330.2 % increase compared to the previous year.Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL
Market Beat·- Bank of America Corp DE raised its holdings in Omnicell, Inc. by 31.3% in the first quarter, owning 580,875 shares valued at $19,390,000. - Omnicell reported second-quarter revenue of $312.21 million and earnings per share of $0.94, surpassing analyst expectations. - Institutional investors and hedge funds own 97.70% of the company's stock, which currently holds a consensus rating of Moderate Buy.Skillsoft (NYSE:SKIL) Stock Price Up 3.8% - Time to Buy?
Market Beat·- Skillsoft Corp. stock traded up 3.8% to reach $7.91 during mid-day trading with a market capitalization of $70.95 million. - The company previously reported quarterly revenue of $94.50 million and an EPS of $1.16 for the quarter ending in June. - Institutional investors and insiders hold significant stakes in the firm, accounting for 87.00% and 16.20% of the stock respectively.Rocket Cos. Inc. Stock Outperforms Competitors On Strong Trading Day
MarketWatch Automated·Bank of America (NYSE:BAC) Trading Down 1.7% - Should You Sell?
Market Beat·- Bank of America’s stock recently traded down 1.7% to $63.1690, accompanied by a trading volume decline of 36% compared to its average session volume. - Recent corporate developments include digital mortgage recognition, Asia Pacific leadership changes, a $250,000 wildfire relief donation, and involvement in an $86.4 million Mexican bond market settlement. - The financial institution reported robust quarterly results with earnings per share of $1.21 and revenue of $31.56 billion, while also announcing an increased quarterly dividend of $0.32 per share.HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's Why
Market Beat·- HUTCHMED shares gapped down to open at $12.30 on Wednesday following mixed recent financial results and varied analyst price target adjustments. - The company reported quarterly earnings per share of $0.05 on revenue of $139.14 million, missing analysts' consensus estimates. - Several institutional investors and hedge funds adjusted their holdings in the biopharmaceutical company during recent quarters.